Vertex Pharma (VRTX) Tops Q1 EPS by 68c; reiterates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex (VRTX) PT Raised to $424 at RBC Capital
May 7, 2024 6:21 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $424.00 (from $417.00) while maintaining a Sector Perform rating.
The analyst comments "A solid 1Q optically, with WW CF sales exceeding expectations, though this was driven mainly by ex-U.S.... More
Vertex (VRTX) PT Lowered to $-- at Stifel
May 7, 2024 6:13 AM EDTStifel analyst Paul Matteis lowered the price target on Vertex (NASDAQ: VRTX) to $-- (from $430.00) while maintaining a Hold rating.
The analyst comments "We remain Hold rated on VRTX. The CF franchise posted a beat (helped by inventory) while VRTX reiterated their... More
